Navigation Links
Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

NEW YORK, Nov. 20 /PRNewswire/ -- announces that a new market research report is available in its catalogue.

Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

Comprehensive Forecasts and Detailed Budget Benchmarks new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.

Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever.

At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.

Uncover Oncology Threats and Opportunities

Equip your teams with the most comprehensive forecast of the oncology marketplace -- from today's stalwarts to tomorrow's blockbusters.

Product Breakdown

112 Anti-cancer drugs in all major classes

15 Adjuncts

Product Profile Components

-Product history

-Competitive and strategic positioning

-Market growth opportunities

-Sales history and projections

-Drug's materiality to company

Budget Brand Resources for Development and Launch

Track real brand spending from the pre-clinical period through the first year on the market

Brand Spending Benchmarks

-Advertising and promotion

-Medical affairs

-Decision support (market research)

-Market access


    Brand Spending Benchmarks

    Average brand spending by budget category:

    - Advertising and promotion

    - Medical affairs

    - Decision support (market research)

    - Market access

    Average brand spending by development stage:

    - Pre-Clinical to phase 2

    - Phase 3a

    - Phase 3b

    - First year on the market

    Product Profiles by Class

    Brand Information

    - Brand and generic name

    - Drug class

    - Delivery mechanism

    - Line of treatment

    Sales Data

    - Historical/current sales

    - Forecasted sales

    Approved Indications

    - Current Product Development Phases

    - Competitive and Strategic Positioning

    - Market Opportunities and Brand Growth

    - Patent, Generic and Litigation Information

    Oncology Indication Analysis

    - Current sales, major drugs and important companies

    - Forecasted sales and assessment of future drugs and market players

    - Pipeline development status

    - Major market events, changes in treatments, patent expirations, etc.

    Companies' Oncology Portfolios

    - Current sales, major drugs and important companies

    - Forecasted sales and assessment of future drugs and market players

    - Pipeline development status

    Companies mentioned

    Amgen AstraZeneca Bristol-Myers Squibb Celgene Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Roche and Genentech Sanofi-Aventis Schering-Plough

    To order this report:

    Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

    More market research reports here!

    Nicolas Bombourg
    US: (805)652-2626
    Intl: +1 805-652-2626

    SOURCE Reportlinker


SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds Biologic Imaging Reagents: Technologies and Global Markets Report
2. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
3. Reportlinker Adds Markets for Advanced Wound Care Technologies Report
4. Reportlinker Adds Antiseptics and Disinfectants Report
5. Reportlinker Adds Commercial Amino Acids Report
6. Reportlinker Adds Membrane & Separation Technology News Review, 2008 Report
7. Reportlinker Adds the Dental Market: Techniques, Equipment and Materials Report
8. Reportlinker Adds Pediatric Health Care Products and Services Report
9. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
10. Reportlinker Adds 2008/2009 Healthcare Research Review Report
11. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: